Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235—a dual PI3K/mTOR inhibitor—and RAD001—an mTOR inhibitor—in 13 en...
Main Authors: | Shoji, Keiko, Oda, Katsutoshi, Kashiyama, Tomoko, Ikeda, Yuji, Nakagawa, Shunsuke, Sone, Kenbun, Miyamoto, Yuichiro, Hiraike, Haruko, Tanikawa, Michihiro, Miyasaka, Aki, Koso, Takahiro, Matsumoto, Yoko, Wada-Hiraike, Osamu, Kawana, Kei, Kuramoto, Hiroyuki, McCormick, Frank, Aburatani, Hiroyuki, Yano, Tetsu, Kozuma, Shiro, Taketani, Yuji |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360787/ |
Similar Items
-
Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
by: Lin, Shu-Fu, et al.
Published: (2012) -
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
by: Gao, Wei, et al.
Published: (2012) -
mTOR inhibitors in cancer therapy
by: Xie, Jianling, et al.
Published: (2016) -
Inhibitors of mTOR in aging and cancer
by: Zhavoronkov, Alexander
Published: (2015) -
NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
by: Sun, Zhihua, et al.
Published: (2015)